MIRM Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

$16.50  -0.62 (-3.62%)
As of 10/18/2021 15:59:37 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/18/2019
Outstanding shares:  30,515,833
Average volume:  406,847
Market cap:   $519,989,794
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    604749101
ISIN:        US6047491013
Sedol:      
Valuation   (See tab for details)
PE ratio:   -11.90
PB ratio:   5.46
PS ratio:   47.27
Return on equity:   -159.95%
Net income %:   -1,392.14%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy